Slide 1: Breakthrough Cardiac Health Monitoring Always by your side
Breakthrough Cardiac Health Monitoring Always by your side 1
Slide 2: Disclaimers
Disclaimers This presentation contains forward - looking statements . All statements other than statements of historical fact contained in this presentation, including statements as to the Company’s future results of operations and financial position, planned products and services, business strategy
Slide 3: Current portable heart monitoring solutions only offer basic monitoring
Current portable heart monitoring solutions only offer basic monitoring A Practical & Portable Solution T o Replicate 12 - Lead ECG Is Needed Practical, portable devices currently in the market can not replicate the gold standard 12 - lead ECG Single - lead options are limited only to sense heart ar
Slide 4: Better diagnosis can improve the management of heart conditions
Better diagnosis can improve the management of heart conditions Heart Disease Kills 17.9 Million People Per Year More in - depth and longitudinal data might lead to earlier diagnosis of heart diseases Multiple heart conditions can be diagnosed with richer data set Fast and accurate heart attack sugg
Slide 5: Outcomes Can Be Improved With Early Heart Attack Diagnosis
Outcomes Can Be Improved With Early Heart Attack Diagnosis First ambulatory device to detect heart attack 5
Slide 6: Vectorcardiography Simplified
Vectorcardiography Simplified Leader In Ambulatory Vectorcardiography Vectorcardiography has clear advantages over ECG * , but additional electrodes and difficulty of interpretation has hampered its use VECG - Unique design allows for measuring 3D heart signals in a portable form factor 3D informati
Slide 7: Clinical Diagnostic Capabilities: Medical Grade Cardiac Health Monitoring
12 - Lead 6 - Lead Clinical Diagnostic Capabilities Medical Grade Cardiac Health Monitoring 3 - Lead ECG Capabilities VECG Unlocks Conditions Beyond Arrhythmias Arrhythmia 1 - Lead Valued at $3.2B Raised $154.3M previous to their undisclosed Series F in 2022 Current Standard of Care ECG 7
Slide 8: Competing Devices Offer Basic Monitoring
Competing Devices Offer Basic Monitoring HEART ATTACK DETECTION 12L ECG CAPABLE INTEGRATES HISTORY & SYMPTOMS USES BASELINE LONG TERM USE POTENTIAL AFIB DETECTION AFLUTTER DETECTION HeartBeam AIMI TM and HeartBeam AIMIGo TM have not yet been evaluated by the FDA and are not approved for clinical use
Slide 9: Current options are fundamentally limited, especially in ability to detect heart attacks
Current options are fundamentally limited, especially in ability to detect heart attacks. Telehealth Application Smartphone Application • Simple and intuitive patient user interface 3D Vector ECG Device • Patient places credit card sized device on chest for a 30 - second signal recording HeartBeam C
Slide 10: Practical ECG System
WEIGHT 28G. (1 OZ.) HEIGHT AND WIDTH CREDIT CARD SIZE THICKNESS 4MM (1/8 INCH) Flat : Not In Use Ejected Electrodes In Use By Patient Retracted chest electrodes Finger electrodes Ejected chest electrodes RECHARGEABLE BATTERY Practical ECG System 10 12 - Lead ECG System Always With You
Slide 11: Portable Vector Electrocardiogram (VECG): Powerful Heart Monitoring In Your Pocket
Portable Vector Electrocardiogram ( VECG ) Powerful Heart Monitoring In Your Pocket 12 - Lead ECG • Technology can replicate a 12 - lead ECG in a true portable form factor • Allows for rich data acquisition with better diagnosis and predictive value, thanks to the 58 parameters that can be measured
Slide 12: MI Detection: HIDES and BSCORE study results
MI Detection Chest Pain Triage Asymptomatic Sensitivity Specificity 93% 95% 83% 70% Cardiologist Cardiologist 97% 56% 94% 54% Sensitivity Specificity Std. Care Std. Care 100% Unique 3D ECG interpretation method has greater accuracy than cardiologists in detecting MIs Proprietary algorithm performanc
Slide 13: Regulatory Strategy To Establish VECG As The Gold Standard
Regulatory Strategy To Establish VECG As The Gold Standard • Initial HeartBeam AIMIGo 510(k) application will be submitted as a 3 - lead (X, Y, and Z) recording device • This will enable initial physician testing and clinical trial use • Subsequent AIMIGo 510(k) application will focus on algorithm t
Slide 14: Platform Enables Multiple Paths To Market
Platform Enables Multiple Paths To Market Direct Pay • Hospital - system - driven: Value significantly outweighs cost • Physician - driven: Cardiologists will prescribe the device • Consumer - driven: Health focused consumers will drive adoption Reimbursement • Develop new CPT Codes where the value
Slide 15: Value Creation Timeline
1 Q2 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Submission V1 Submission V2 Early Market Testing V2 Launch V2 Value Creation Timeline * This timeline is for illustrative purposes only and is meant to portray a sequence of events, not their estimated timing. ` Q2 2024 Q3 2024 V1 Clearance V2 Cleara
Slide 16: Predictive AI Functionality & Scale Drive Value
Cost Value Hardware Scale AI Implementation Time Other Heart Conditions Service Scale MI Detection Predictive AI Functionality & Scale Drive Value 16
Slide 17: Market Segments
Market Segments Who pays Stage 1 Stage 2 Stage 3 Cardiologist in the Cloud Patient Concierge Practices Patient/Practice Clinical Trials CRO/Pharma Hospital at Home Provider Value Based Cardiology Groups Hospital/Practice Post MI Discharge Hospital Unique Reimbursement Codes Medicare/Private Payors A
Slide 18: Intellectual Property & Product Pipeline
• Multiple granted patents, including foundational resistive network enabling Z - lead • Potential additional patents around improving accuracy and business model • Additional prototypes to lower cost • Foundational patent granted: VECG to 12 - lead upon pressing electrodes with fingers • Capital be
Slide 19: Licensing Opportunities on Multiple Fronts
Licensing Opportunities on Multiple Fronts ECG Devices ECG Patch Smartwatches 19
Slide 20: Key Medical Contributors
Key Medical Contributors MIKE GIBSON, MD PETER ZIMETBAUM, MD ALEXEI SHVILKIN, MD NIRAJ VARMA, MD STEVE ELLIS, MD PETER FITZGERALD, MD, PhD PHILIP SAGER, MD RAJ DASH, MD JOHN JEFFERIES, MD TOM DEERING, MD CHARLIE BROWN, MD JEFFREY J. OYLER, MD BARRY MANGEL, MD BRETT CANNON, MD World Class Advisors 20
Slide 21: Highly Experienced Management
Rich Ferrari Executive Chairman Marga Ortigas – Wedekind Board Member Wim Elfrink Board Member George de Urioste Board Member Branislav Vajdic, PhD CEO & Founder Peter Fitzgerald, MD, PhD Chief Medical Officer Ken Persen Chief Technical Officer Rick Brounstein Chief Financial Officer Significant exp
Slide 22: Cap Structure
Cap Structure Stock Options Number of Stock Options Weighted Avg. Exercise Price Outstanding Sept. 30, 22 2,101,921 $1.69 Vested Sept. 30, 22 556,005 $1.33 Warrants Number of Warrants Weighted Avg. Exercise Price Outstanding Sept. 30, 22 3,908,276 $5.43 Exercisable Sept. 30, 22 3,501,004 $6.06 Stock
Slide 23: The Offering
The Offering Offering Amount $ 15 Million Security Straight Common Stock Price Per Share To Be Determined Offer Type Registered Public Offering 23
Slide 24: Use Of Proceeds
Use Of Proceeds Clinical & Regulatory $2,000 Research & Development $7,000 Sales & Marketing $1,000 General & Administrative $5,000 Total $15,000 In thousands 24 Enables 12 - month runway to reach value - inflection milestones
Slide 25: Investment Highlights
Investment Highlights Novel Way T o Capture Rich Electrical Signal Data From The Heart 12 - Lead ECG • Only device you can carry in your pocket that can replicate the gold standard 12 - lead ECG • Allows for rich data acquisition with better diagnosis and predictive value Intellectual Property • Fou
Slide 26: Breakthrough Cardiac Health Monitoring Always by your side
Breakthrough Cardiac Health Monitoring Always by your side 26